Certara, Inc. (Nasdaq: CERT) announced a partnership with Nvidia to integrate the Nvidia BioNeMo Agent Toolkit into Certara's AI platform, combining the company's biosimulation software, regulatory expertise, and proprietary datasets with agentic AI frameworks.

According to a press release, the BioNeMo Agent Toolkit will function as one of several agentic frameworks within Certara's platform, working alongside the company's biosimulation models and scientific teams. The toolkit is designed to allow AI agents to operate across life sciences workflows, including dosing strategy optimization, clinical dataset analysis, patient and trial simulation, ADMET property evaluation, and regulatory evidence assembly.

Chief Executive Officer Jon Resnick said in the statement: "Agentic AI combined with Certara's world-class scientists, validated models, and data keeps the scientist in the loop while delivering the speed, scale, and reproducibility our clients need to generate integrated evidence for regulators."

Chief Technology Officer and Chief AI Officer Chris Bouton added: "Our collaboration with Nvidia and addition of the BioNeMo Agent Toolkit to the integrated platform helps accelerate that vision" of computationally simulating human biology to transform drug discovery and development.

Certara states it serves more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies. The company is headquartered in Radnor, Pennsylvania.